NASDAQ: EIDX - Eidos Therapeutics, Inc.

Yield per half year: +178.07%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Eidos Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Eidos Therapeutics, Inc.

Eidos Therapeutics, Inc., клиническая биофармацевтическая компания, специализируется на разработке препаратов для лечения заболеваний, вызванных транстиретином (TTR) или амилоидозом (ATTR). Он разрабатывает AG10, который находится в фазе 3 клинических испытаний, представляет собой перорально вводимую небольшую молекулу, предназначенную для стабилизации тетрамерного TTR, тем самым останавливая в самом начале серию молекулярных событий, которые приводят к ATTR. Компания была основана в 2013 году со штаб-квартирой в Сан-Франциско, штат Калифорния. Eidos Therapeutics, Inc.

more details
является дочерней компанией BridgeBio Pharma, Inc.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-06-20
ISIN US28249H1041
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт http://www.eidostx.com
Цена ао 122.21
Change price per day: 0% (122.21)
Change price per week: -0.2612% (122.53)
Change price per month: -4.3% (127.7)
Change price per 3 month: +66.75% (73.29)
Change price per half year: +178.07% (43.95)
Change price per year: +120.95% (55.31)
Change price per 3 year: 0% (122.21)
Change price per 5 year: 0% (122.21)
Change price per 10 year: 0% (122.21)
Change price per year to date: +43.62% (85.09)
All parameters

Underestimation

Title Value Grade
P/S 36595.5 1
P/BV 38.7 1
P/E 0 0
EV/EBITDA -49.6 0
Total: 2

Efficiency

Title Value Grade
ROA, % -59.27 0
ROE, % -70.31 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 470270.37 10
Yield Ebitda, % 0 0
Yield EPS, % 1938.46 10
Total: 8
More

Institutions Volume Share, %
RA Capital Management, LLC 2163271 5.57
Aisling Capital Management LP 1123630 2.89
Cormorant Asset Management, LLC 993185 2.56
BlackRock Fund Advisors 710640 1.83
Perceptive Advisors LLC 686922 1.77
Redmile Group, LLC 466205 1.21
Opaleye Management Inc 315550 0.81
Board of Ttees Leland Stanford Jr Univ 265670 0.68
Northern Trust Investments Inc 206054 0.53
AIG Asset Management (U.S), LLC 200000 0.51
Harbor Capital Advisors Inc 114140 0.29
Artisan Partners Holdings LP 43872 0.11
Parkman Healthcare Partners LLC 41091 0.11
GLG Partners LP 30010 0.08
Indecap AB 29597 0.08
Assenagon Asset Management SA 26387 0.07
Bayview Asset Management Co., Ltd. 24300 0.06
Equitable Investment Management 22332 0.06
Artisan Partners LP 22234 0.06
BlackRock Advisors (UK) Limited 17094 0.04
Erste Asset Management GmbH 13600 0.04
AllianceBernstein (Luxembourg) S.à r.l. 3328 0.01
Defiance ETFs, LLC 890 0
Hennion & Walsh, Inc 100 0

ETF Share, % Profitability for 1 year, % Dividends, %
ProShares UltraShort Nasdaq Biotechnology 0.25 -40.36 1.76



Head Job title Payment Year of birth
Dr. Neil Kumar CEO & Director 1979 (46 years)
Dr. Uma Sinha Chief Scientific Officer & Director 1957 (68 years)
Dr. Cameron Turtle DPHIL, Ph.D. Chief Bus. Officer 1990 (35 years)
Dr. Jonathan C. Fox FACC, M.D., Ph.D. Pres & Chief Medical Officer 1957 (68 years)
Dr. Isabella Graef M.D. Co-Founder & Board Advisor 1965 (60 years)
Dr. Mamoun Alhamadsheh Ph.D., Pharm.D. Co-Founder
Mr. Franco Valle Sr. VP of Fin., Principal Accounting Officer & Sec. 1981 (44 years)
Mr. Matt Outten Chief Commercial Officer
Dr. Hoyoung Huh Consultant 1969 (56 years)

Address: United States, San Francisco, 101 Montgomery Street - open in Google maps, open in Yandex maps
Website: http://www.eidostx.com